Please ensure Javascript is enabled for purposes of website accessibility

Can Boston Scientific's New Approval Boost Sales?

By Dan Carroll - Apr 17, 2013 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Growth from the medical device company's smaller divisions offers hope that the firm can turn around its sales slump.

Investors have gotten their money's worth out of Boston Scientific's (BSX 2.64%) stock lately. Shares of the medical device maker have surged by more than 30% in the past six months alone, rising higher despite the company's troubles. Sales have fallen into a slump at Boston Scientific, led lower by the company's cardiac rhythm management, or CRM, business, which produces everything from pacemakers to implantable defibrillators. This is an industry on the decline -- Medtronic (MDT -0.36%), a leader in the medical device field, has seen its own CRM sales slump in recent quarters, while Boston Sci rival St. Jude Medical (STJ) has similarly had its top line hammered by its CRM division's falling revenue.

Boston Scientific is more than just a cardiovascular device maker, however -- and its smaller, growing divisions invite hope for the company's future despite the slump in its core business. In this video, Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss one of Boston Scientific's hot growing businesses and why investors should pay attention to the company's upcoming earnings report to see whether it's making the right moves to turn around its lagging sales.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
$41.20 (2.64%) $1.06
St. Jude Medical, Inc. Stock Quote
St. Jude Medical, Inc.
Medtronic plc Stock Quote
Medtronic plc
$99.08 (-0.36%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.